Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Baseline results of a living systematic review for COVID-19 clinical trial registrations
Authors: Philippe J. Guérin
Brittany J. Maguire
Alistair R.D. McLean
Sumayyah Rashan
Emilia Sitsofe Antonio
Jayshree Bagaria
Zineb Bentounsi
Matthew Brack
Fiona Caldwell
Verena Ilona Carrara
Barbara Wanjiru Citarella
Prabin Dahal
Vitalis Fambombi Feteh
Marius H.B. Guérin
Kalynn Kennon
Kathinka Bilton Lahaut
Gerald Jamberi Makuka
Roland Ngu
Sopuruchukwu Obiesie
Caitlin Richmond
Sauman Singh-Phulgenda
Samantha Strudwick
Carina S.B. Tyrrell
Austin Schwinn
David King
Paul N. Newton
Ric N. Price
Laura Merson
Kasia Stepniewska
Public Health England
Muhimbili University of Health and Allied Sciences
Shoklo Malaria Research Unit
University of Cambridge
Menzies School of Health Research
L'Institut de santé globale, Genève
Mahosot Hospital, Lao
Mahidol University
Universitetet i Oslo
Nuffield Department of Medicine
University of Oxford Medical Sciences Division
Infectious Diseases Data Observatory (IDDO)
International Severe Acute Respiratory & Emerging Infection Consortium (ISARIC)
Health and Human Development (2HD) Research Network
Exaptive Inc.
Keywords: Biochemistry, Genetics and Molecular Biology
Issue Date: 1-Jan-2020
Citation: Wellcome Open Research. Vol.5, (2020)
Abstract: © 2020 Maguire BJ et al. Background: Since the coronavirus disease 2019 (COVID-19) outbreak was first reported in December 2019, many independent trials have been planned that aim to answer similar questions. Tools allowing researchers to review studies already underway can facilitate collaboration, cooperation and harmonisation. The Infectious Diseases Data Observatory (IDDO) has undertaken a living systematic review (LSR) to provide an open, accessible and frequently updated resource summarising characteristics of COVID-19 study registrations. Methods: Review of all eligible trial records identified by systematic searches as of 3 April 2020 and initial synthesis of clinical study characteristics were conducted. In partnership with Exaptive, an open access, cloud-based knowledge graph has been created using the results. Results: There were 728 study registrations which met eligibility criteria and were still active. Median (25 th, 75 th percentile) sample size was 130 (60, 400) for all studies and 134 (70, 300) for RCTs. Eight lower middle and low income countries were represented among the planned recruitment sites. Overall 109 pharmacological interventions or advanced therapy medicinal products covering 23 drug categories were studied. Majority (57%, 62/109) of them were planned only in one study arm, either alone or in combination with other interventions. There were 49 distinct combinations studied with 90% (44/49) of them administered in only one or two study arms. The data and interactive platform are available at Conclusions: Baseline review highlighted that the majority of investigations in the first three months of the outbreak were small studies with unique treatment arms, likely to be unpowered to provide solid evidence. The continued work of this LSR will allow a more dependable overview of interventions tested, predict the likely strength of evidence generated, allow fast and informative filtering of relevant trials for specific user groups and provide the rapid guidance needed by investigators and funders to avoid duplication of efforts.
ISSN: 2398502X
Appears in Collections:Scopus 2020

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.